GMAB (genmab.com) Koefisien nilai perusahaan marang pendapatan

Simbol resmi perusahaan Genmab AS (GMAB)

Genmab A/S net profit relies on royalties from global pharma behemoths, which minimizes dependence on individual studies. The EV/Sales multiple clearly captures the daily market valuation of the business relative to revenue, with the value stabilizing at 8093.20. Unique antibody platforms provide indirect pricing power, while the company's impeccable scientific standing ensures the trust of global oncologists.

genmab.com (GMAB): Multiplikator EV/Sales saka 23.11.2025 nganti 19.11.2026

Rincian metrik keuangan lan pasar Genmab (GMAB)

- rega lan prakiraan konsensus rega:
- indikator valuasi pasar bisnis:
Pambiji fundamental perusahaan:Genmab A/S GMAB
Sampel barang genmab.com

The development of Genmab A/S's own commercial network as part of its M&A transformation directly impacts capitalization and operating cash flows. The EV/Sales ratio is calculated as the sum of market capitalization and net debt divided by revenue, allowing for a business valuation independent of its financing structure. This chart reflects the efficiency of asset integration and the market's revaluation of the company's ability to independently monetize its drugs.